Immunotherapies are the new new in modern medical miracles. David Giljohann, CEO Exicure (XCUR)

Oct 14, 01:06 AM


(Photo:Cabinets of curiosities, such as that of Ole Worm, were centers of biological knowledge in the early modern period, bringing organisms from across the world together in one place. Before the Age of Exploration, naturalists had little idea of the sheer scale of biological diversity.

View author information

Public Domain

File:Musei Wormiani Historia.jpg

Uploaded: 21 December 2005 )

Twitter: @BatchelorShow

Immunotherapies are the new new in modern medical miracles. David Giljohann, CEO Exicure (XCUR)

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Our proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. We are based outside of Chicago, IL.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure's intellectual property portfolio includes over 120 pending patent applications and over 55 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.